IL6, another STAT3-activating cytokine, has been of much interest and antibodies that neutralize IL6 or block IL6 receptor (R) α are in clinical trials for ovarian, prostate, and renal cancers [35, 36]. Here, STAT3 is linked to renal carcinoma.